Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [NCI-R183-14] to DLX3
- Suitable for: WB
- Reacts with: Mouse, Human
Product nameAnti-DLX3 antibody [NCI-R183-14]
See all DLX3 primary antibodies
DescriptionRabbit monoclonal [NCI-R183-14] to DLX3
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Human
Synthetic peptide within Human DLX3. The exact sequence is proprietary. The immunogen is from the TDO polymorphism of DLX3
- WB: Saos-2 cell transfected with mouse TetOFFv5DLX3/flag TDO untreated with DOX(Doxorubicin 2µg/ml); Saos-2 cell transfected with human TetOFFv5DLX3/flag TDO untreated with DOX(Doxorubicin 2µg/ml).
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab211492 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 45, 38 kDa (predicted molecular weight: 32 kDa).|
FunctionLikely to play a regulatory role in the development of the ventral forebrain. May play a role in craniofacial patterning and morphogenesis.
Involvement in diseaseDefects in DLX3 are a cause of trichodentoosseous syndrome (TDO) [MIM:190320]. TDO is an autosomal dominant syndrome characterized by enamel hypoplasia and hypocalcification with associated strikingly curly hair.
Defects in DLX3 are the cause of amelogenesis imperfecta type 4 (AI4) [MIM:104510]; also known as amelogenesis imperfecta hypomaturation-hypoplastic type with taurodontism. AI4 is an autosomal dominant defect of enamel formation associated with enlarged pulp chambers.
Sequence similaritiesBelongs to the distal-less homeobox family.
Contains 1 homeobox DNA-binding domain.
- Information by UniProt
- AI4 antibody
- Distal less homeo box 3 antibody
- DLX 3 antibody
All lanes : Anti-DLX3 antibody [NCI-R183-14] (ab211492) at 1/1000 dilution
Lane 1 : Saos-2 (Human osteosarcoma cell line) cell transfected with mouse TetOFFv5DLX3/flag TDO treated with DOX(Doxorubicin 2µg/ml)
Lane 2 : Saos-2 (Human osteosarcoma cell line) cell transfected with mouse TetOFFv5DLX3/flag TDO untreated with DOX(Doxorubicin 2µg/ml)
Lane 3 : Saos-2 (Human osteosarcoma cell line) cell transfected with human TetOFFv5DLX3/flag TDO treated with DOX(Doxorubicin 2µg/ml)
Lane 4 : Saos-2 (Human osteosarcoma cell line) cell transfected with human TetOFFv5DLX3/flag TDO untreated with DOX(Doxorubicin 2µg/ml)
Predicted band size: 32 kDa
Observed band size: 38,45 kDa why is the actual band size different from the predicted?
Exposure time: 30 seconds
Blocking/Dilution buffer: 5% NFDM/TBST.
This product only recognizes DLX3 carrying the TDO (Tricho-Dento-Osseous syndrome) frameshift mutation.
ab211492 has not yet been referenced specifically in any publications.